Publications

Authors:

Porcaro, Antonio Benito; Panunzio, Andrea; Orlando, Rossella; Montanaro, Francesca; Baielli, Alberto; Artoni, Francesco; Gallina, Sebastian; Bianchi, Alberto; Mazzucato, Giovanni; Serafin, Emanuele; Patuzzo, Giulia Marafioti; Veccia, Alessandro; Rizzetto, Riccardo; Brunelli, Matteo; Migliorini, Filippo; Bertolo, Riccardo; Tafuri, Alessandro; Cerruto, Maria Angela; Antonelli, Alessandro

Title:

The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b

Year:

2024

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

Sì

Name of journal:

INTERNATIONAL BRAZ J UROL

ISSN of journal:

1677-6119

N° Volume:

50

Number or Folder:

4

Page numbers:

450-458

Keyword:

Lymph Node Excision; Minimally Invasive Surgical Procedures; Prostatic Neoplasms

Short description of contents:

Purpose: We assessed the prognostic impact of the 2012 Briganti nomogram on prostate cancer (PCa) progression in intermediate-risk (IR) patients presenting with PSA &lt;10ng/mL, ISUP grade group 3, and clinical stage up to cT2b treated with robot assisted radical prostatectomy eventually associated with extended pelvic lymph node dissection. Materials and methods: From January 2013 to December 2021, data of surgically treated IR PCa patients were retrospectively evaluated. Only patients presenting with the above-mentioned features were considered. The 2012 Briganti nomogram was assessed either as a continuous and a categorical variable (up to the median, which was detected as 6%, vs. above the median). The association with PCa progression, defined as biochemical recurrence, and/or metastatic progression, was evaluated by Cox proportional hazard regression models. Results: Overall, 147 patients were included. Compared to subjects with a nomogram score up to 6%, those presenting with a score above 6% were more likely to be younger, had larger/palpable tumors, presented with higher PSA, underwent tumor upgrading, harbored non-organ confined disease, and had positive surgical margins at final pathology. PCa progression, which occurred in 32 (21.7%) cases, was independently predicted by the 2012 Briganti nomogram both considered as a continuous (Hazard Ratio [HR]:1.04, 95% Confidence Interval [CI]:1.01-1.08;p=0.021), and a categorical variable (HR:2.32; 95%CI:1.11-4.87;p=0.026), even after adjustment for tumor upgrading. Conclusions: In IR PCa patients with PSA &lt;10ng/mL, ISUP grade group 3, and clinical stage up to cT2b, the 2012 Briganti nomogram independently predicts PCa progression. In this challenging subset of patients, this tool can identify prognostic subgroups, independently by upgrading issues.

Web page:

https://www.intbrazjurol.com.br/pdf/vol50n04/IBJU20240003.pdf

Product ID:

140005

Handle IRIS:

11562/1127906

Last Modified:

June 5, 2024

Bibliographic citation:

Porcaro, Antonio Benito; Panunzio, Andrea; Orlando, Rossella; Montanaro, Francesca; Baielli, Alberto; Artoni, Francesco; Gallina, Sebastian; Bianchi, Alberto; Mazzucato, Giovanni; Serafin, Emanuele; Patuzzo, Giulia Marafioti; Veccia, Alessandro; Rizzetto, Riccardo; Brunelli, Matteo; Migliorini, Filippo; Bertolo, Riccardo; Tafuri, Alessandro; Cerruto, Maria Angela; Antonelli, Alessandro, The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b «INTERNATIONAL BRAZ J UROL» , vol. 50 , n. 4 , 2024 , pp. 450-458

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo